NCT02231931 is a Phase 1 clinical trial of Digoxin in Healthy, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT02231931?

NCT02231931 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT02231931?

Interventions in NCT02231931: Digoxin, Rosuvastatin, Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin, Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin, Metformin hydrochloride, Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin, Furosemide.

Is NCT02231931 still recruiting?

NCT02231931 is currently completed. Last updated 24 October 2023.

Last reviewed 2023-10-24 · How we verify

NCT02231931

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin

Completed Phase 1 Last updated 24 October 2023

What this trial tests

Phase 1 trial testing Digoxin in Healthy in 24 participants. Completed in 1 January 2015.

Timeline

1 September 2014

Primary endpoint
1 January 2015

1 January 2015

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 September 2014
Primary completion	1 January 2015
Estimated completion	1 January 2015
Sites	1 location across Germany

Drugs / interventions tested

Digoxin (digoxin) — full drug profile →
Rosuvastatin (rosuvastatin) — full drug profile →
Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin — full drug profile →
Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin — full drug profile →
Metformin hydrochloride — full drug profile →
Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin — full drug profile →
Furosemide (furosemide) — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 18 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the mutual interaction potential of digoxin, furosemide, metformin, and rosuvastatin when given alone or together as a cocktail, and to investigate the effect of high doses of metformin or furosemide on pharmacokinetics of the other cocktail compounds

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.
Stopfer P, Giessmann T, Hohl K, Sharma A, et al · · 2016 · cited 54× · PMID 27256812 · DOI 10.1002/cpt.406

Verify or expand the search:

Other trials of Digoxin

Trials testing the same drug.

NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting
NCT07223671 — Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy · Phase 1 · completed
NCT07321509 — Digoxin After Acute Heart Failure · Phase 4 · recruiting
NCT07215260 — A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken · Phase 1 · completed
NCT07118215 — A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin · Phase 1 · recruiting

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02231931 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 24 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02231931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing